Glenmark is proud to bring a revolution in diabetes management by introducing for the first time in the world, its researched, global, SGLT2 inhibitor - Remogliflozin . Remogliflozin has been extensively researched across countries and is backed by 26 clinical studies involving more than 2500 patients . With the launch of Remogliflozin, Glenmark is poised to bring a new paradigm in diabetes treatment for better patient outcome . Glenmark invites you for an interactive webinar on 23 rd May 2019 from 9.00 pm onwards . In this webinar, Chairperson Dr. Ambrish Mithal Speakers Dr. Rajeev Chawla will talk about “Paradigm Shift in The Management of T2DM: SGLT2i” Dr.
Monashis Sahu will talk about “Remogliflozin- Clinical Evidence & Therapeutic Place in Type 2 Diabetes Mellitus” Panelists Dr. Ambrish Mithal Dr. Rajeev Chawla Dr. Monashis Sahu Dr. Ashok Kumar Jhighan Dr. JPS Shawney We invite you…
